Drug General Information
Drug ID
D09JES
Former ID
DNC001270
Drug Name
Sampatrilat
Drug Type
Small molecular drug
Indication Hypotension [ICD9: 458, 796.3; ICD10:I95] Phase 2 [525516]
Structure
Download
2D MOL

3D MOL

Formula
C26H40N4O9S
Canonical SMILES
CS(=O)(=O)NC(CCCCN)C(=O)NC(CC(=O)O)CC1(CCCC1)C(=O)NC(CC<br />2=CC=C(C=C2)O)C(=O)O
InChI
1S/C26H40N4O9S/c1-40(38,39)30-20(6-2-5-13-27)23(34)28-18(15-22(32)33)16-26(11-3-4-12-26)25(37)29-21(24(35)36)14-17-7-9-19(31)10-8-17/h7-10,18,20-21,30-31H,2-6,11-16,27H2,1H3,(H,28,34)(H,29,37)(H,32,33)(H,35,36)/t18-,20-,21-/m0/s1
InChIKey
DGTDHMSPXWLPNJ-JBACZVJFSA-N
CAS Number
CAS 91-45-2
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Neutral endopeptidase Target Info Modulator [525516]
KEGG Pathway Renin-angiotensin system
Hematopoietic cell lineage
Protein digestion and absorption
Alzheimer's disease
NetPath Pathway EGFR1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Reactome Metabolism of Angiotensinogen to Angiotensins
WikiPathways Metabolism of Angiotensinogen to Angiotensins
Primary Focal Segmental Glomerulosclerosis FSGS
Alzheimers Disease
References
Ref 525516Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.
Ref 525516Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.